Alternatively activated RAW264.7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinoma

2009 ◽  
Vol 107 (1) ◽  
pp. 134-143 ◽  
Author(s):  
Bicheng Zhang ◽  
Jun Wang ◽  
Juan Gao ◽  
Yan Guo ◽  
Xi Chen ◽  
...  
2021 ◽  
Vol 2 (2) ◽  
pp. 100583
Author(s):  
Isabella Del Priore ◽  
Sai Ma ◽  
Jonathan Strecker ◽  
Tyler Jacks ◽  
Lindsay M. LaFave ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Xiaoxiao Zhu ◽  
Qiang Guo ◽  
Jing Zou ◽  
Bin Wang ◽  
Zhen Zhang ◽  
...  

Macrophages, an important type of immune cells, are generally polarized to classically activated macrophage (M1) or alternatively activated macrophage (M2) to respond to environmental stimuli. Signal transducer and activator of transcription 1 (STAT1), a very important transcription factor, can promote M1 macrophage polarization. However, the mechanisms of regulating STAT1 in macrophage polarization remain unclear. In the present study, STAT1 was markedly elevated, however, miR-19a-3p was down-regulated in interferon (IFN)-γ and lipopolysaccharide (LPS) treated RAW264.7 cells, and dual-luciferase reporter assay identified that miR-19a-3p directly targeted STAT1 by binding to its 3′UTR. Up-regulated miR-19a-3p inhibited M1 polarization by targeting STAT1/interferon regulatory factor 1 (IRF1) and vice versa in vitro. Consistently, overexpression of miR-19a-3p in LPS treated mice by systemically administering agomiR-19a-3p effectively reduced the inflammation in mouse lung tissues, and inhibited M1 macrophage polarization via suppressing STAT1/IRF1 pathway. In summary, our study confirmed that miR-19a-3p, as a direct regulator of STAT1, inhibited M1 macrophages polarization. The miR-19a-3p/STAT1/IRF1 pathway can potentially be used to design novel immunotherapy for modulating macrophage polarization.


2021 ◽  
Author(s):  
Benjamin D Stein ◽  
John R Ferrarone ◽  
Eric E Gardner ◽  
Jae Won Chang ◽  
David Wu ◽  
...  

KRAS is the most frequently mutated oncogene in human lung adenocarcinomas (hLUAD) and activating mutations in KRAS frequently co-occur with loss-of-function mutations in the tumor suppressor genes, TP53 or STK11/LKB1. However, mutation of all three genes is rarely observed in hLUAD, even though engineered mutations of all three genes produces a highly aggressive lung adenocarcinoma in mice (mLUAD). Here we provide an explanation of this difference between hLUAD and mLUAD by uncovering an evolutionary divergence in regulation of the glycolytic enzyme triosephosphate isomerase (TPI1). Using KRAS/TP53 mutant hLUAD cell lines, we show that TPI1 enzymatic activity can be altered via phosphorylation at Ser21 by the Salt Inducible Kinases (SIKs) in an LKB1-dependent manner; this allows modulation of glycolytic flux between completion of glycolysis and production of glycerol lipids. This metabolic flexibility appears to be critical in rapidly growing cells with KRAS and TP53 mutations, explaining why loss of LKB1 creates a metabolic liability in these tumors. In mice, the amino acid at position 21 of TPI1 is a Cys residue which can be oxidized to alter TPI1 activity, allowing regulation of glycolytic flux balance without a need for SIK kinases or LKB1. Our findings reveal an unexpected role for TPI1 in metabolic reprogramming and suggest that LKB1 and SIK family kinases are potential targets for treating KRAS/TP53 mutant hLUAD. Our data also provide a cautionary example of the limits of genetically engineered murine models as tools to study human diseases such as cancers.


Cancer Cell ◽  
2020 ◽  
Vol 38 (2) ◽  
pp. 212-228.e13 ◽  
Author(s):  
Lindsay M. LaFave ◽  
Vinay K. Kartha ◽  
Sai Ma ◽  
Kevin Meli ◽  
Isabella Del Priore ◽  
...  

2011 ◽  
Vol 11 (6) ◽  
pp. 592-598 ◽  
Author(s):  
Shuli Man ◽  
Wenyuan Gao ◽  
Yanjun Zhang ◽  
Zhen Liu ◽  
Lulu Yan ◽  
...  

2008 ◽  
Vol 233 (1) ◽  
pp. 81-91 ◽  
Author(s):  
Linda M. Sargent ◽  
Mang X. Ensell ◽  
Anne-Carine Ostvold ◽  
Kimberly T. Baldwin ◽  
Michael L. Kashon ◽  
...  

2008 ◽  
Vol 25 (8) ◽  
pp. 855-864 ◽  
Author(s):  
Shuli Man ◽  
Yanjun Zhang ◽  
Wenyuan Gao ◽  
Lulu Yan ◽  
Chaoyi Ma

Author(s):  
Tamihiro Kamata ◽  
Esraa Al Dujaily ◽  
Salwa Alhamad ◽  
Tsz Y. So ◽  
Olga Margaritaki ◽  
...  

Anti-cancer properties of statins are controversial, and possibly context-dependent. Recent pathology/epidemiology studies of human lung adenocarcinoma showed reduced protumourigenic macrophages associated with a shift to lower grade tumours amongst statin users but, paradoxically, worse survival compared to non-users. To investigate the mechanisms involved, we have characterised mouse lung adenoma/adenocarcinoma models treated with atorvastatin. Here we show that atorvastatin suppresses premalignant disease by inhibiting the recruitment of protumourigenic macrophages to the tumour microenvironment, manifested in part by suppression of Rac-mediated CCR1 ligand secretion. However, prolonged atorvastatin treatment leads to drug resistance and progression of lung adenomas into invasive disease. Pathological progression is not driven by acquisition of additional driver mutations or immunoediting/evasion but is associated with stromal changes including the development of desmoplastic stroma containing Gr1+ myeloid cells and tertiary lymphoid structures (TLS). These findings show that any chemopreventive functions of atorvastatin in lung adenocarcinoma are overridden by stromal remodelling in the long term, thus providing mechanistic insight into the poor survival of lung adenocarcinoma patients with statin use.


2014 ◽  
Vol 111 (13) ◽  
pp. 4952-4957 ◽  
Author(s):  
Kate D. Sutherland ◽  
Ji-Ying Song ◽  
Min Chul Kwon ◽  
Natalie Proost ◽  
John Zevenhoven ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document